Bone metastases in advanced prostate cancer. Management

6/20/22, 12:19 AM 17128
12. Sartor O, Heinrich D, Mariados N, et al. Re-treatment with radium-223: first experience
from an international, open-label, phase I/II study in patients with castration-resistant
prostate cancer and bone metastases. Ann Oncol 2017; 28:2464.
13. Smith M, Parker C, Saad F, et al. Addition of radium-223 to abiraterone acetate and
prednisone or prednisolone in patients with castration-resistant prostate cancer and bone
metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
Oncol 2019; 20:408.
14. Gillessen S, Choudhury A, Rodriguez-Vida A, et al. Decreased fracture rate by mandating bo
ne protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide
versus enzalutamide alone: An updated safety analysis (abstract). J Clin Oncol 39, 2021 (sup
p15; abstr 5002). Abstract available online at https://meetinglibrary.asco.org/record/19674
4/abstract (Accessed on June 17, 2021).
15. Saad F, Carles J, Gillessen S, et al. Radium-223 and concomitant therapies in patients with
metastatic castration-resistant prostate cancer: an international, early access, open-label,
single-arm phase 3b trial. Lancet Oncol 2016; 17:1306.
16. Etchebehere EC, Milton DR, Araujo JC, et al. Factors affecting (223)Ra therapy: clinical
experience after 532 cycles from a single institution. Eur J Nucl Med Mol Imaging 2016;
43:8.
17. Morris MJ, Loriot Y, Sweeney CJ, et al. Radium-223 in combination with docetaxel in patients
with castration-resistant prostate cancer and bone metastases: a phase 1 dose
escalation/randomised phase 2a trial. Eur J Cancer 2019; 114:107.
18. Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and
89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 2007; 28:623.
19. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the
efficacy of strontium-89 adjuvant to local field external beam irradiation in the
management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys
1993; 25:805.
20. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and
external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31:33.
21. Oosterhof GO, Roberts JT, de Reijke TM, et al. Strontium(89) chloride versus palliative local
field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of
the European Organisation for Research and Treatment of Cancer, Genitourinary Group.
Eur Urol 2003; 44:519.
22. James ND, Pirrie SJ, Pope AM, et al. Clinical Outcomes and Survival Following Treatment of
Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89,
https://www.uptodate.com/contents/17128/print 18/27